NIH study to test treatment for fatty liver disease in children

January 12, 2012 By Leslie Curtis and Amy F. Reiter, National Institutes of Health

With the launch of a new clinical trial supported by the National Institutes of Health, researchers are working to determine whether treating children diagnosed with the most severe form of fatty liver disease with a drug called cysteamine will help improve the liver.

The trial, called Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic in (CyNCh),will enroll 160 boys and girls ages 8 to 17 with nonalcoholic fatty (NAFLD). The participants will receive cysteamine or placebo by mouth twice a day for a year. There are no weight cutoffs or percentiles for the children participating in CyNCh. However, more than 90 percent of the children are expected to be overweight or obese. Participants need a baseline biopsy that confirms severe NAFLD to be eligible for the study. Children with poorly managed diabetes, heart disease, and other will be excluded.

NAFLD covers a range of severity from simple liver disease without injury, called steatosis, to the more concerning , or NASH, which includes fat accumulation, inflammation, and . Most children with fatty liver disease are overweight and resistant to insulin, a hormone that regulates energy. The only way to distinguish NASH from other forms of fatty liver disease is with a .

"We did not see fatty liver disease in children until recently," said Edward Doo, M.D., NASH Clinical Research Network project scientist and director of the Liver Diseases Program at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which is funding the study in collaboration with Raptor Pharmaceutical of Novato, Calif., which makes the drug and will provide it to the trial. "Fatty liver disease affects about 17 percent of children in the United States. This rise in the number of children with NAFLD most likely mirrors the increase in obesity, which affects more than 16 percent of American children and teens," Dr. Doo said.

Results from a small pilot study using cysteamine in 11 children with NASH suggest that it improves liver enzymes by reducing toxins that can damage the liver. Cysteamine is approved to treat cystinosis, a genetic disease that causes the amino acid cystine to accumulate in the kidneys, liver, eyes, brain, and white blood cells. Modest weight loss through diet and physical activity may help some children with fatty liver disease, but it is a treatment option that seldom helps people meet their goals. "We know that following a weight loss plan for many children and adults can be daunting, especially if they have limited access to healthy food options that are low in fat, added sugars, and calories, and infrequent opportunities for physical activity," said Joel E. Lavine, M.D., Ph.D., a CyNCh principal investigator and professor of pediatrics at Columbia University, New York City. "Hopefully, this trial will move us closer to finding a safe and effective treatment that helps children with fatty liver disease."

NAFLD can be a precursor to NASH, which may progress to cirrhosis, liver failure and liver cancer. NAFLD may also increase a patient’s risk of developing heart disease. A healthy liver helps the body remove harmful chemicals from the blood, fight infection and digest food. If too much scar tissue forms, the liver could fail. Then a liver transplant is required. "We are concerned that the disease may advance as children become adults and increase their risk for cirrhosis, liver failure, liver transplantation, and death as adults," said Stephen P. James, M.D., director of the NIDDK’s Digestive Diseases and Nutrition Division. "This multicenter, double-blind trial offers researchers and NIDDK an opportunity to rigorously assess how safe and effective cysteamine is in treating children with NASH, as well as to reveal new avenues worthy of scientific study."

The following clinical centers are conducting the CyNCh trial:

• Children's Memorial Hospital, Chicago
• Cincinnati Children’s Hospital Medical Center
• Columbia University, New York City
• Indiana University, Indianapolis
• Mount Sinai Medical Center, New York City
• St. Louis University
• Texas Children's Hospital, Houston
• University of California, San Diego
• University of California, San Francisco
• University of Washington, Seattle

For more information:

• NIDDK's NASH Clinical Research Network: jhuccs1.us/nash/open/centers/centers.htm
• NIDDK's Action Plan for Liver Disease Research: www.liverplan.niddk.nih.gov
• National Digestive Diseases Information Clearinghouse: digestive.niddk.nih.gov
• Weight-control Information Network: www.win.niddk.nih.gov
• ClinicalTrials.gov: www.clinicaltrials.gov

Explore further: Vitamin E or metformin may not be effective for treating liver disease in children and teens

Related Stories

Vitamin E or metformin may not be effective for treating liver disease in children and teens

April 26, 2011
In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according ...

Obesity and diabetes epidemics spur increase in nonalcoholic steatohepatitis

December 14, 2011
Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity ...

Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C

September 27, 2011
Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C ...

Recommended for you

Scientists a step closer to predicting epidemics

July 13, 2018
Ecologists at the University of Georgia have taken an important step in their efforts to develop an early warning system for infectious disease outbreaks.

Researchers identify target for novel malaria vaccine

July 13, 2018
A Yale-led team of researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites ...

Higher income and being married protect older people from broken bones

July 13, 2018
Research led by scientists from the Medical Research Council Lifecourse Epidemiology Unit (MRC LEU) at the University of Southampton has shown that a higher income and being married reduces the risk of experiencing a broken ...

Gammaherpesviruses linked to tumors in macaques with simian immunodeficiency virus

July 12, 2018
Viruses known as gammaherpesviruses may raise the risk of cancer in macaques infected with Simian Immunodeficiency Virus or Simian Human Immunodeficiency Virus (SIV/SHIV), according to new research published by Vickie Marshall ...

Scientists find protein exploited by virus ravaging West Africa

July 12, 2018
A research team from several institutions being led by the University of California San Diego has deciphered a key component behind a rising epidemic of pathogens that the World Health Organization (WHO) recently added to ...

How a Mediterranean diet could reduce osteoporosis

July 11, 2018
Eating a Mediterranean-type diet could reduce bone loss in people with osteoporosis—according to new research from the University of East Anglia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.